MX2021012171A - Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1). - Google Patents

Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1).

Info

Publication number
MX2021012171A
MX2021012171A MX2021012171A MX2021012171A MX2021012171A MX 2021012171 A MX2021012171 A MX 2021012171A MX 2021012171 A MX2021012171 A MX 2021012171A MX 2021012171 A MX2021012171 A MX 2021012171A MX 2021012171 A MX2021012171 A MX 2021012171A
Authority
MX
Mexico
Prior art keywords
cadherin
klrg1
antibodies
killer cell
cell lectin
Prior art date
Application number
MX2021012171A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth Evan Thompson
Stefano Vicenzo Gulla
Original Assignee
Abcuro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcuro Inc filed Critical Abcuro Inc
Publication of MX2021012171A publication Critical patent/MX2021012171A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021012171A 2019-04-09 2020-04-09 Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1). MX2021012171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962831713P 2019-04-09 2019-04-09
PCT/US2020/027498 WO2020210512A1 (en) 2019-04-09 2020-04-09 Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies

Publications (1)

Publication Number Publication Date
MX2021012171A true MX2021012171A (es) 2021-12-10

Family

ID=72748720

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012171A MX2021012171A (es) 2019-04-09 2020-04-09 Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1).

Country Status (13)

Country Link
US (3) US11180561B2 (https=)
EP (1) EP3952999A4 (https=)
JP (1) JP7560476B2 (https=)
KR (1) KR20210150506A (https=)
CN (1) CN114040800B (https=)
AU (1) AU2020272939A1 (https=)
BR (1) BR112021019128A2 (https=)
CA (1) CA3136625A1 (https=)
IL (1) IL287044A (https=)
MX (1) MX2021012171A (https=)
SG (1) SG11202110610VA (https=)
WO (1) WO2020210512A1 (https=)
ZA (1) ZA202107414B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020060781A1 (en) 2018-09-17 2020-03-26 Abcuro, Inc. Anti-klrg1 antibodies
WO2022056289A1 (en) * 2020-09-11 2022-03-17 National Jewish Health Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells
AU2022246164A1 (en) * 2021-03-26 2023-09-28 The Brigham And Women’S Hospital, Inc. Anti-klrg1 antibodies
WO2022204529A1 (en) * 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
MX2024001277A (es) * 2021-07-26 2024-02-15 Abcuro Inc Anticuerpos agotadores del miembro 1 de la subfamilia g del receptor tipo lectina de celulas asesinas (klrg1).
WO2024072872A2 (en) * 2022-09-27 2024-04-04 The Brigham And Women's Hospital, Inc. Klrg1 signalling therapy for infectious disease
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)
WO2026072990A1 (en) 2024-09-27 2026-04-02 Abcuro, Inc. Methods of treating t-cell large granular lymphocytic leukemia

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
WO2001070805A2 (en) 2000-03-17 2001-09-27 Gemini Science, Inc. Soluble mast cell function associated antigen (mafa) pharmaceutical compositions and methods of making and using them
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
JP3536039B2 (ja) 2001-05-08 2004-06-07 独立行政法人 科学技術振興機構 Ｈｔｌｖ−ｉ腫瘍に対する抗腫瘍抗原又はその抗原エピトープ
GB0114107D0 (en) 2001-06-09 2001-08-01 Medical Res Council Respiratory syncytial virus
CA2680344A1 (en) 2007-03-14 2008-11-20 Woodruff Emlen Humaneered anti-factor b antibody
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
JP2012025694A (ja) 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd 癌治療剤
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR20140138971A (ko) 2012-03-28 2014-12-04 제넨테크, 인크. 항-hcmv 이디오타입 항체 및 이들의 용도
WO2016013672A1 (ja) 2014-07-25 2016-01-28 国立研究開発法人理化学研究所 メモリーインバリアントｎｋｔ細胞マーカー
CA3005491A1 (en) 2015-11-17 2017-05-26 Glaxosmithkline Intellectual Property Development Limited Binding agonists for treatment of neurological and other disorders
UA126115C2 (uk) * 2016-03-08 2022-08-17 Янссен Байотек, Інк. Антитіло до gitr
WO2017210523A1 (en) * 2016-06-03 2017-12-07 The Brigham And Women's Hospital Klrg1 signaling therapy
AU2017326003A1 (en) 2016-09-16 2019-04-11 Children's Medical Center Corporation KLRG1 depletion therapy
US20210002373A1 (en) * 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof

Also Published As

Publication number Publication date
WO2020210512A1 (en) 2020-10-15
US20220089747A1 (en) 2022-03-24
EP3952999A4 (en) 2023-01-25
US20250101114A1 (en) 2025-03-27
BR112021019128A2 (pt) 2022-01-04
CN114040800A (zh) 2022-02-11
JP7560476B2 (ja) 2024-10-02
JP2022528721A (ja) 2022-06-15
KR20210150506A (ko) 2021-12-10
WO2020210512A9 (en) 2020-11-19
AU2020272939A1 (en) 2021-11-11
IL287044A (en) 2021-12-01
AU2020272939A8 (en) 2021-12-02
EP3952999A1 (en) 2022-02-16
US11180561B2 (en) 2021-11-23
US20200325233A1 (en) 2020-10-15
CN114040800B (zh) 2024-09-20
CA3136625A1 (en) 2020-10-15
SG11202110610VA (en) 2021-10-28
ZA202107414B (en) 2023-02-22
US12139541B2 (en) 2024-11-12

Similar Documents

Publication Publication Date Title
MX2021012171A (es) Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1).
Kotanides et al. Bispecific targeting of PD-1 and PD-L1 enhances T-cell activation and antitumor immunity
US20250066492A1 (en) Agonistic anti tnfr2 antibody molecules
CN112513082B (zh) Cd38抗体变体及其用途
JP7284557B2 (ja) 医薬組成物
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
CN117186225A (zh) 抗tigit抗体及其作为治疗和诊断的用途
US20230096030A1 (en) Bispecific antibodies against cd9 and cd7
JP2016533763A (ja) 抗ｐｄ−１抗体並びにその治療及び診断のための使用
US20230125234A1 (en) Anti cd44-ctla4 bispecific antibodies
CA3117864A1 (en) Novel antagonistic anti tnfr2 antibody molecules
PE20230839A1 (es) Agentes de union a lair-1 y metodos para su uso
Dougall et al. Retracted: Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity
Xu et al. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity
Susek et al. Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
JP2022553927A (ja) Ｉｌｔ－２阻害剤での癌の処置
Davies et al. Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer
Kapelski et al. Influence of the bispecific antibody IgG subclass on T cell redirection
MX2022005862A (es) Metodos de tratamiento de anemia hemolitica autoinmune caliente mediante el uso de anticuerpos anti-fcrn.
US20240400703A1 (en) Antibodies capable of binding to ox40, variants thereof and uses thereof
Iijima et al. Selective expression of a C-type lectin receptor, Clec12b, on skin mast cells
Zhu et al. Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition
Yang et al. A fc-engineered NKG2D× B7-H3 bispecific antibody enhances the antitumor activity by orchestrating cytotoxic lymphocytes
WO2025114541A1 (en) Antibodies capable of binding to ox40 in combination therapy
KR20240082341A (ko) MerTK에 특이적으로 결합하는 항체 또는 이의 단편, 및 항종양제